The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention

Pruski M, Krysiak R, Okopien B.
Diabetes Care. 2009 May 12. [Epub ahead of print]. 

Objective: To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia. Research Design and Methods: We studied 128 type 2 diabetes patients with mixed dyslipidemia complying throughout the study with lifestyle intervention who were randomized twice, initially to either metformin or placebo and then to micronized fenofibrate or placebo. Results: Fenofibrate alleviated diabetic dyslipidemia-induced changes in plasma hsCRP, fibrinogen and PAI-1, and in monocyte cytokine release, while metformin or lifestyle intervention improved mainly glucose and lipid metabolism. The strongest pleiotropic effect was observed when fenofibrate was added to metformin. Conclusions: Fenofibrate, particularly administered together with metformin, is superior to metformin and lifestyle intervention in exhibiting beneficial effects on systemic inflammation, hemostasis and monocyte secretory function in type 2 diabetic patients with mixed dyslipidemia. 

PMID: 19435959 [PubMed - as supplied by publisher] 


Last Modified: 3/1/2013